Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma

Safe and effective glaucoma treatment remains a critical task in ophthalmology. Newly introduced medications, in addition to mandatory registration trials, are also evaluated in real-world clinical settings. Purpose. This study assesses the efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in patients with primary open-angle glaucoma (POAG) in real-world clinical settings. Material and methods. The study included 55 patients aged 46 to 75 years with stage I and II POAG. The initial mean intraocular pressure (IOP) was 24.07±1.31 mm Hg. All patients were prescribed the fixed combination of dorzolamide/timolol. Results. The mean IOP after 1, 3, 6, and 12 weeks of therapy was 19.20±2.46, 18.48±2.04, 17.88±1.88, and 17.62±1.63 mm Hg, respectively. After 12 weeks of therapy, IOP reduction to 18 mm Hg was observed in 63.64% of patients, a reduction of 20% or more from baseline in 81.82% of patients, and a reduction of 30% or more in 14.55% of patients. No serious adverse events were recorded during the observation period. Conclusion. This study confirms the high hypotensive efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol).